1. IXEMPRA (ixabepilone) Prescribing Information. Bristol-Myers Squibb Company; Princeton, NJ. Jan 2010.

2. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients
     with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407-3414.

3. Data on file. IXEM002. Study CA163081. Bristol-Myers Squibb: Princeton, NJ; 2009.

4. Thomas ES, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane
     treatment. J Clin Oncol. 2007;25:5210-5217.

5. Vahdat L, Fein LE, Karwal MW, et al. Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast
     cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase III studies. Poster presented at the
     San Antonio Breast Cancer Symposium. Dec. 12, 2008. Poster Number 6117.

6. Rugo HS, Roche H, Thomas E, et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors:
     a pooled analysis of patients from two large phase III clinical studies. Poster presented at the San Antonio Breast Cancer
     Symposium. Dec. 12, 2008. Poster Number 3057.

7. ASHP Guidelines on Handling Hazardous Drugs. American Society of Health-System Pharmacists. ASHP Web site.
     Available at: http://www.ashp.org. Accessed October 7, 2009.